Notícias e Atividades da Serina Therapeutics

A Serina Therapeutics pertence à Lineage Cell Therapeutics.

Lineage Cell Therapeutics é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Lineage Cell Therapeutics é uma empresa listada sob o símbolo LCTX (US).

Veja o organograma con seus 16 executivos principais

Biografias mais buscadas da Serina Therapeutics

• Steve Ledger, Chief Executive Officer and Director
• Karen Wilson, Director
• Richard Marshall, Director

Recentes movimentos de executivos em Serina Therapeutics

• Stephen Brannan, ingressou na Companhia como Director  (Notícia publicada em 23 de maio de 2025).
• Jay Venkatesan, ingressou na Companhia como Director  (Notícia publicada em 13 de fevereiro de 2025).
• Karen Wilson, ingressou na Companhia como Director  (Notícia publicada em 15 de janeiro de 2025).

Criar um alerta
para seguir os movimentos de executivos da Serina Therapeutics.

Lineage Cell Therapeutics possui 2.350 concorrentes concorrentes Astellas Gene Therapies (Estados Unidos), Eurofins (Luxemburgo) e Lonza (Suíça).

Popular M&A news in Biotecnologia

• Eli Lilly has announced the acquisition of Verve Therapeutics  (publicado em 17 de junho de 2025).
• Sirius Therapeutics acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 16 de junho de 2025).
• BioNTech has announced the acquisition of CureVac  (publicado em 12 de junho de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships da WIRB-Copernicus Group
• Jasbir Seehra - Chief Executive Officer and Chairman of the Board da Keros Therapeutics
• Deepika Verma - Associate Director of Data Science and Digitalization da Wheeler Bio

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Serina Therapeutics

• Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit
• Serina Therapeutics to Present at Tribe Public’s Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024
• Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients
• Serina Therapeutics Makes Grants to New Employees Under Inducement Plan
• Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights
• Serina Therapeutics to Present at the 14th Annual Injectables Summit
• Enable Injections Announces Agreement with Sobi® to Develop and Distribute Aspaveli® in Combination with enFuse® in Sobi Territories
• Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
• Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics Summit
• Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights
• View more press releases Close

Redes sociais sobre Serina Therapeutics

• Serina Therapeutics na Wikipedia, Google News e Yahoo Finance
• Serina Therapeutics na LinkedIn, Twitter e YouTube